

WHAT IS CLAIMED IS:

1. A protein comprising an amino acid sequence of SEQ ID No. 1 of sequence listing, or an amino acid
5 sequence at least partly homologous or analogous to said sequence, and having proliferation inhibitory activity on cancer cells or cell death inducing activity, and its fragments.
- 10 2. A protein comprising an amino acid sequence homologous to said amino acid sequence of SEQ ID No. 1 of sequence listing, and having proliferation inhibitory activity on cancer cells or cell death inducing activity.
- 15 3. A protein comprising amino acids 61-89 and 497-514 of SEQ ID No. 1 of said sequence listing, and having proliferation inhibitory activity on cancer cells or cell death inducing activity.
- 20 4. A gene coding said protein defined in any one of claims 1 to 3 or its fragment.
5. A gene comprising DNA sequence of SEQ ID No. 2
25 of sequence listing, or DNA sequence at least partly homologous or analogous to said sequence.

6. A monoclonal antibody to said protein as defined in any one of claims 1 to 3 or its fragment.

7. The monoclonal antibody of claim 6 selected from the group consisting of I38A (NATIONAL INSTITUTE OF BIOSCIENCE AND HUMAN TECHNOLOGY, AGENCY OF INDUSTRIAL SCIENCE AND TECHNOLOGY, International Deposit No. FERM BP-5872), monoclonal antibody I32D (NATIONAL INSTITUTE OF BIOSCIENCE AND HUMAN TECHNOLOGY, AGENCY OF INDUSTRIAL SCIENCE AND TECHNOLOGY, International Deposit No. FERM BP-5873), and monoclonal antibody I310H (NATIONAL INSTITUTE OF BIOSCIENCE AND HUMAN TECHNOLOGY, AGENCY OF INDUSTRIAL SCIENCE AND TECHNOLOGY, International Deposit No. FERM BP-5874).

15

8. A reagent for qualifying apoptosis comprising at least one member selected from the group consisting of said protein as defined in any one of claims 1 to 3 and its fragment, said monoclonal antibody defined in claim 6, said monoclonal antibody defined in claim 7, and mixtures thereof.

9. A carcinostatic agent comprising said protein as defined in any one of claims 1 to 3 and its fragment as an active component.

25

10. The carcinostatic agent of claim 9 further

comprising said monoclonal antibody as defined in claim
6 or 7.